IQVIA Holdings Inc. (NYSE:IQV) Stock Has Consensus Price Target of $294.21 According to Analysts

IQVIA Holdings Inc. (NYSE:IQV) has been assigned an average recommendation of “Moderate Buy” from the twenty-one ratings firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating, sixteen have assigned a buy rating and two have issued a strong buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $294.21.

A number of research analysts have weighed in on the stock. JPMorgan Chase & Co. lifted their price objective on shares of IQVIA from $295.00 to $325.00 and gave the company an “overweight” rating in a report on Wednesday, October 28th. Weiss Ratings lowered IQVIA from a “hold (c+)” rating to a “sell (d+)” rating in a research note on Wednesday, October 28th. UBS Group started coverage on IQVIA in a report on Wednesday, September 30th. They issued a “buy” rating and a $345.00 price target for the company. Truist Financial increased their price target on IQVIA from $329.00 to $346.00 and gave the stock a “buy” rating in a research report on Wednesday, October 28th. Finally, William Blair raised IQVIA to a “strong-buy” rating in a report on Tuesday, July 28th.

IQVIA Trading Down 0.2%

Shares of NYSE:IQV opened at $274.73 on Friday. IQVIA has a 12-month low of $154.50 and a 12-month high of $284.50. The company has a market capitalization of $45.28 billion, a PE ratio of 33.38, a PEG ratio of 2.44 and a beta of 1.16. The business has a 50 day moving average of $267.53 and a two-hundred day moving average of $211.60. The company has a current ratio of 0.83, a quick ratio of 0.83 and a debt-to-equity ratio of 2.18.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, October 27th. The medical research company reported $3.34 EPS for the quarter, topping analysts’ consensus estimates of $3.26 by $0.08. The business had revenue of $4.43 billion for the quarter, compared to analysts’ expectations of $4.37 billion. IQVIA had a net margin of 8.05% and a return on equity of 30.02%. The business’s revenue was up 8.0% on a year-over-year basis. During the same quarter last year, the company earned $3.00 EPS. As a group, analysts forecast that IQVIA will post 11.53 EPS for the current year.

Insider Activity

In other news, insider James G. Berkshire sold 2,668 shares of the company’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total transaction of $697,228.44. Following the completion of the sale, the insider owned 10,890 shares of the company’s stock, valued at $2,845,883.70. This represents a 19.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.70% of the stock is owned by insiders.

Hedge Funds Weigh In On IQVIA

Several hedge funds and other institutional investors have recently modified their holdings of IQV. Advisors Asset Management Inc. purchased a new stake in IQVIA during the 3rd quarter valued at about $596,000. Private Wealth Asset Management LLC raised its holdings in IQVIA by 1,501.5% in the 3rd quarter. Private Wealth Asset Management LLC now owns 3,219 shares of the medical research company’s stock valued at $875,000 after acquiring an additional 3,018 shares during the last quarter. Private Advisor Group LLC lifted its stake in IQVIA by 385.5% in the 3rd quarter. Private Advisor Group LLC now owns 8,010 shares of the medical research company’s stock worth $2,153,000 after purchasing an additional 6,360 shares in the last quarter. Focus Advisor Solutions LLC lifted its stake in IQVIA by 46.8% in the 3rd quarter. Focus Advisor Solutions LLC now owns 7,418 shares of the medical research company’s stock worth $1,995,000 after purchasing an additional 2,365 shares in the last quarter. Finally, Meeder Asset Management Inc. boosted its holdings in shares of IQVIA by 1,518.8% during the 3rd quarter. Meeder Asset Management Inc. now owns 3,788 shares of the medical research company’s stock worth $1,018,000 after purchasing an additional 3,554 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

About IQVIA

IQVIA Holdings Inc. provides clinical research services, healthcare data and analytics, and technology solutions to pharmaceutical, biotechnology, medical-device, and other healthcare organizations. Its services support the development and commercialization of medicines and other healthcare products. The company’s offerings include clinical trial planning and management, real-world data and evidence, consulting, and software and technology platforms for life sciences research and commercial operations.